Research at Aurigene Oncology Ltd. has led to the discovery of a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor AU-MALT1-01 for the potential treatment of B-cell lymphomas including diffuse large B-cell lymphoma (DLBCL).